Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test
Skeletal safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains uncharted, with emerging evidence suggesting a divergence between mono- and dual-agonist therapies. GLP-1RA monotherapy appears bone-neutral, with modest or no adverse effects on bone mineral density (BMD), whilst dual a...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2026-07-01
|
| Serier: | Diagnostics |
| Fag: | |
| Online adgang: | https://www.mdpi.com/2075-4418/16/13/2128 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
